EMA Authorised: Enflonsia (clesrovimab) — Merck Sharp Dohme Limited

View source ↗

Summary

The EMA authorises Enflonsia (clesrovimab) from Merck Sharp & Dohme Limited for use in Respiratory Syncytial Virus vaccines.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infection

Drugs mentioned

• ENFLONSIA (CLESROVIMAB)

Snippet

Status: Authorised. Therapeutic area: Respiratory Syncytial Virus Vaccines. MAH: Merck Sharp Dohme Limited. Decision date: 03/06/2026